stoxline Quote Chart Rank Option Currency Glossary
  
Adamas Pharmaceuticals, Inc. (ADMS)
8.22  0 (0%)    12-31 19:00
Open: 8.24
High: 8.25
Volume: 3,151,400
  
Pre. Close: 8.22
Low: 8.18
Market Cap: 0(M)
Technical analysis
2022-01-28 4:23:49 PM
Short term     
Mid term     
Targets 6-month :  9.63 1-year :  11.25
Resists First :  8.25 Second :  9.63
Pivot price 8.22
Supports First :  8.2 Second :  8.18
MAs MA(5) :  8.22 MA(20) :  8.22
MA(100) :  7.42 MA(250) :  6.04
MACD MACD :  0.01 Signal :  0.01
%K %D K(14,3) :  57.14 D(3) :  57.14
RSI RSI(14): 73.52
52-week High :  8.25 Low :  4.01
Price, MAs and Bollinger Bands


Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Headline News

Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - GlobeNewswire

Tue, 26 Oct 2021
Adamas Pharmaceuticals Stock: An Acceptable Buyout At The Perfect Time (NASDAQ:ADMS) - Seeking Alpha

Mon, 11 Oct 2021
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - GlobeNewswire

Mon, 01 Mar 2021
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Business Wire

Wed, 24 Feb 2021
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering - Business Wire

Tue, 23 Feb 2021
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 46 (M)
Shares Float 31 (M)
Held by Insiders 1.7 (%)
Held by Institutions 80.3 (%)
Shares Short 1,600 (K)
Shares Short P.Month 2,510 (K)
Stock Financials
EPS -1.61
EPS Est Next Qtrly -1.17
EPS Est This Year -3.77
EPS Est Next Year -3.43
Book Value (p.s.) -0.1
Profit Margin -66.82 %
Operating Margin -45.14 %
Return on Assets (ttm) -16.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 16.89 %
Gross Profit (p.s.) 1.58
Sales Per Share 1.8
EBITDA (p.s.) -0.81
Qtrly Earnings Growth 0 %
Operating Cash Flow -51 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -5.14
PEG Ratio 0
Price to Book value -91.34
Price to Sales 4.55
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android